{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:47:15Z","timestamp":1792432035825,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jcf.2023.09.006","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T13:22:17Z","timestamp":1695129737000},"page":"349-353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Effects of elexacaftor\/tezacaftor\/ivacaftor on liver fibrosis markers in adults with cystic fibrosis"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2763-8990","authenticated-orcid":false,"given":"Daniel H","family":"Tewkesbury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6112-2093","authenticated-orcid":false,"given":"Jennifer","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6326-4431","authenticated-orcid":false,"given":"Peter J","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowland J","family":"Bright-Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Piper","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varinder","family":"Athwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3232-1055","authenticated-orcid":false,"given":"Andrew M","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10212","key":"10.1016\/j.jcf.2023.09.006_bib0001","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the f508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jcf.2023.09.006_bib0002","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jcf.2023.09.006_bib0003","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jcf.2023.09.006_bib0004","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jcf.2023.01.007","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on liver tests at a large single adult cystic fibrosis centre","volume":"22","author":"Tewkesbury","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.09.006_bib0005","article-title":"Delayed hepatic necrosis in a cystic fibrosis patient taking elexacaftor\/tezacaftor\/ivacaftor (Kaftrio)","volume":"34","author":"Salehi","year":"2021","journal-title":"Respir Med Case Rep,"},{"key":"10.1016\/j.jcf.2023.09.006_bib0006","first-page":"A2113","article-title":"Acute liver failure in a patient with cystic fibrosis taking triple combination modulator","volume":"203","author":"Sharma","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.jcf.2023.09.006_bib0007","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1007\/s00261-017-1211-7","article-title":"Evaluation of hepatic fibrosis: a review from the society of abdominal radiology disease focus panel","volume":"42","author":"Horowitz","year":"2017","journal-title":"Abdom Radiol"},{"issue":"5","key":"10.1016\/j.jcf.2023.09.006_bib0008","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/liv.12113","article-title":"Utility of transient elastography in the non-invasive evaluation of cystic fibrosis liver disease","volume":"33","author":"Kitson","year":"2013","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.jcf.2023.09.006_bib0009","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/hep.29217","article-title":"Adult-onset cystic fibrosis liver disease: diagnosis and characterization of an underappreciated entity","volume":"66","author":"Koh","year":"2017","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jcf.2023.09.006_bib0010","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jcf.2009.08.001","article-title":"Non-invasive liver elastography (Fibroscan) for detection of cystic fibrosis-associated liver disease","volume":"8","author":"Witters","year":"2009","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2023.09.006_bib0011","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/liv.15544","article-title":"Increase of liver stiffness and altered bile acid metabolism after triple CFTR modulator initiation in children and young adults with cystic fibrosis","volume":"43","author":"Schnell","year":"2023","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.jcf.2023.09.006_bib0012","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jcf.2020.05.002","article-title":"A longitudinal assessment of non-invasive biomarkers to diagnose and predict cystic fibrosis-associated liver disease","volume":"19","author":"Karnsakul","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2023.09.006_bib0013","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/MPG.0000000000002413","article-title":"Liver ultrasound patterns in children with cystic fibrosis correlate with noninvasive tests of liver disease","volume":"69","author":"Ling","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"10.1016\/j.jcf.2023.09.006_bib0014","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jcf.2020.07.018","article-title":"Barrier to using APRI and GPR as identifiers of cystic fibrosis liver disease","volume":"20","author":"Sellers","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.09.006_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e21861","article-title":"Improving detection of cystic fibrosis related liver disease using liver fibrosis assessment tools","author":"Scott","year":"2023","journal-title":"Heliyon"},{"issue":"Suppl 2","key":"10.1016\/j.jcf.2023.09.006_bib0016","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S1569-1993(11)60006-4","article-title":"Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease","volume":"10","author":"Debray","year":"2011","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.09.006_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101547","article-title":"Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"51","author":"Cao","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.jcf.2023.09.006_bib0018","first-page":"93","article-title":"Changes in share wave elastography after lumacaftor\/ivacaftor treatment in children with cystic fibrosis","volume":"18","author":"Kanavaki","year":"2022","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.jcf.2023.09.006_bib0019","unstructured":"European Medicines Agency. Kaftrio, summary of product characteristics. 2020 [cited 2022 20 May]; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kaftrio-epar-product-information_en.pdf."},{"issue":"2","key":"10.1016\/j.jcf.2023.09.006_bib0020","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jcf.2012.11.010","article-title":"Cirrhosis and other liver disease in cystic fibrosis","volume":"12","author":"Flass","year":"2013","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2023.09.006_bib0021","doi-asserted-by":"crossref","first-page":"e42139","DOI":"10.1371\/journal.pone.0042139","article-title":"Non-invasive evaluation of cystic fibrosis related liver disease in adults with ARFI, transient elastography and different fibrosis scores","volume":"7","author":"Karlas","year":"2012","journal-title":"PLOS One"},{"issue":"2","key":"10.1016\/j.jcf.2023.09.006_bib0022","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2023.09.006_bib0023","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/MCP.0000000000000824","article-title":"Emerging clinical perspectives in cystic fibrosis liver disease","volume":"27","author":"Athwal","year":"2021","journal-title":"Curr Opin Pulm Med"},{"issue":"6","key":"10.1016\/j.jcf.2023.09.006_bib0024","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s13318-022-00791-8","article-title":"Phase 1 study to assess the safety and pharmacokinetics of elexacaftor\/tezacaftor\/ivacaftor in subjects without cystic fibrosis with moderate hepatic impairment","volume":"47","author":"Viswanathan","year":"2022","journal-title":"Eur J Drug Metab Pharmacokinet"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323009104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323009104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T08:23:48Z","timestamp":1772353428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323009104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1569199323009104"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.09.006","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of elexacaftor\/tezacaftor\/ivacaftor on liver fibrosis markers in adults with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}